These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 8643041)

  • 21. Topoisomerase II antagonism and anticancer activity of coordinated derivatives of [RuCl(2)(C(6)H(6))(dmso)].
    Vashisht Gopal YN; Konuru N; Kondapi AK
    Arch Biochem Biophys; 2002 May; 401(1):53-62. PubMed ID: 12054487
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and topoisomerase poisoning activity of A-ring and E-ring substituted luotonin A derivatives.
    Nacro K; Zha CC; Guzzo PR; Jason Herr R; Peace D; Friedrich TD
    Bioorg Med Chem; 2007 Jun; 15(12):4237-46. PubMed ID: 17418582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome.
    Vispé S; Vandenberghe I; Robin M; Annereau JP; Créancier L; Pique V; Galy JP; Kruczynski A; Barret JM; Bailly C
    Biochem Pharmacol; 2007 Jun; 73(12):1863-72. PubMed ID: 17391647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor?
    Gombos DS; Hungerford J; Abramson DH; Kingston J; Chantada G; Dunkel IJ; Antoneli CB; Greenwald M; Haik BG; Leal CA; Medina-Sanson A; Schefler AC; Veerakul G; Wieland R; Bornfeld N; Wilson MW; Yu CB
    Ophthalmology; 2007 Jul; 114(7):1378-83. PubMed ID: 17613328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationships between topoisomerase II inhibition, sequence-specificity and DNA binding mode of dicationic diphenylfuran derivatives.
    Bailly C; Dassonneville L; Carrasco C; Lucas D; Kumar A; Boykin DW; Wilson WD
    Anticancer Drug Des; 1999 Feb; 14(1):47-60. PubMed ID: 10363027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Topoisomerase II inhibition and high yield of endoreduplication induced by the flavonoids luteolin and quercetin.
    Cantero G; Campanella C; Mateos S; Cortés F
    Mutagenesis; 2006 Sep; 21(5):321-5. PubMed ID: 16950806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design of new topoisomerase II inhibitors based upon a quinobenzoxazine self-assembly model.
    Zeng Q; Kwok Y; Kerwin SM; Mangold G; Hurley LH
    J Med Chem; 1998 Oct; 41(22):4273-8. PubMed ID: 9784102
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of eukaryotic DNA topoisomerases and topoisomerase-directed drug effects.
    Boege F
    Eur J Clin Chem Clin Biochem; 1996 Nov; 34(11):873-88. PubMed ID: 8960461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis and topoisomerase II inhibition activity of 4'-demethylepipodophyllotoxin-lexitropsin conjugates.
    Gupta R; al-Said NH; Oreski B; Lown JW
    Anticancer Drug Des; 1996 Jun; 11(4):325-38. PubMed ID: 8679055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapy-related acute promyelocytic leukaemia.
    Fenaux P; Detourmignies L
    Br J Haematol; 1994 Jun; 87(2):445. PubMed ID: 7947301
    [No Abstract]   [Full Text] [Related]  

  • 32. [Topoisomerase II as a cellular receptor of various antineoplastic drugs].
    Szmigiero L
    Postepy Biochem; 1988; 34(3):147-52. PubMed ID: 2855749
    [No Abstract]   [Full Text] [Related]  

  • 33. [DNA-topoisomerase II: Cellular targets of antineoplastic agents].
    Le Guern M
    Pathol Biol (Paris); 1987 Apr; 35(4):343-5. PubMed ID: 3035465
    [No Abstract]   [Full Text] [Related]  

  • 34. [Second cancers associated with the cancer treatment and their possible control].
    Abe T; Nomura K
    Nihon Rinsho; 2003 Jun; 61(6):1045-51. PubMed ID: 12806958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topoisomerase II and the response to antileukemic therapy.
    Kaufmann SH; Gore SD; Miller CB; Jones RJ; Zwelling LA; Schneider E; Burke PJ; Karp JE
    Leuk Lymphoma; 1998 Apr; 29(3-4):217-37. PubMed ID: 9684921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA topoisomerases.
    Osheroff N
    Biochim Biophys Acta; 1998 Oct; 1400(1-3):1-2. PubMed ID: 9867354
    [No Abstract]   [Full Text] [Related]  

  • 37. [Gyrase inhibitor: central nervous system side effects].
    Schnuch A
    Dtsch Med Wochenschr; 1987 Apr; 112(14):569. PubMed ID: 3030684
    [No Abstract]   [Full Text] [Related]  

  • 38. Chemotherapy-induced secondary malignancies.
    Vega-Stromberg T
    J Infus Nurs; 2003; 26(6):353-61. PubMed ID: 14624175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can the genotoxicity of chemotherapy be predicted?
    Pui CH; Relling MV
    Lancet; 2004 Sep 11-17; 364(9438):917-8. PubMed ID: 15364174
    [No Abstract]   [Full Text] [Related]  

  • 40. Modifying risks of secondary leukemias: is drug scheduling important?
    Karp JE; Smith MA
    J Natl Cancer Inst; 1996 Dec; 88(24):1787-9. PubMed ID: 8961963
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.